To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Open-label trial of atomo… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Open-label trial of atomoxetine hydrochloride in adults with ADHD.

Journal article
Authors Mats Johnson
Mats Cederlund
Maria Råstam
Björn Areskoug
Christopher Gillberg
Published in Journal of Attention Disorders
Volume 13
Issue 5
Pages 539-545
ISSN 1087-0547
Publication year 2010
Published at Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Pages 539-545
Language en
Keywords Adrenergic Uptake Inhibitors, Administration & dosage, Adverse effects, Adult, Attention Deficit Disorder with Hyperactivity, Drug therapy, Drug Administration Schedule, Female, Humans, Intention to Treat Analysis, Longitudinal Studies, Male, Middle Aged, Patient Selection, Propylamines, Administration & dosage, Adverse effects, Time, Treatment Outcome
Subject categories Child and adolescent psychiatry


Background: While atomoxetine is an established treatment for attention-deficit/hyperactivity disorder in children, few studies have examined its efficacy for adults. Methods: Open-label trial of atomoxetine in 20 individuals with ADHD, aged 19-47 years, for 10 weeks, and a total of one year for responders. Results: Ten patients met primary efficacy criteria at 10 weeks. Only one patient completed the whole study. Six patients discontinued before 10 weeks and thirteen at 10 weeks or later, mainly because of side-effects (aggression, depressed mood, raised liver enzymes, thyroid hormones, diastolic blood pressure), decreasing efficacy or non-compliance. Conclusion: Fifty percent responded to treatment, but only one patient (5%) felt sufficient improvement to continue for one year. Dosage may have been too low, and baseline impairment too high, for atomoxetine to have sufficient effect on ADHD symptoms in our group of adults. The majority had few side-effects, but several terminated treatment because of adverse effects.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?